Hayden AI Wins Barcelona Innova Lab Mobility Competition to Pilot Technology in Barcelona
3.7.2024 09:45:00 EEST | Business Wire | Press release
Hayden AI, a leader in artificial intelligence and geospatial analytics, has won €100,000 from the Barcelona Innova Lab Mobility competition to deploy Hayden AI’s mobile perception technology on public transport buses in Barcelona for a six-month pilot. This competitive award program is hosted by the Barcelona City Council, the Barcelona Institute of Technology for the Habitat, Fira de Barcelona, and Tomorrow.Mobility.
This award marks Hayden AI’s largest international deployment. Hayden AI’s industry-leading mobile perception platform detects parking and moving violations in bus stops and bus lanes that slow down and obstruct public transport, and is used by major transport authorities in North America to improve the efficiency, safety, sustainability, and accessibility of their bus networks.
“Winning this competition to bring our mobile perception platform to Barcelona — a city known across the globe for leading urban mobility and sustainability forward — is incredibly exciting for us,” said Chris Carson, CEO and founder of Hayden AI. “Transport authorities partner with Hayden AI because our technology helps them deliver safer, more reliable, accessible bus service, and encourages more people to ride public transport in the process. We’re honored to work with Barcelona on testing our technology in this incredible city.”
Hayden AI is the United States market leader in mobile automated bus lane enforcement and bus stop enforcement, with hundreds of bus-mounted, AI-powered camera systems installed on transit buses across the country. This technology is proven to reduce vehicle collisions, improve bus on-time performance, and help ensure that bus stops are accessible to people with disabilities.
In addition to Barcelona, Hayden AI is launching an automated bus stop enforcement pilot in Braga (Portugal) funded by the European Institute of Innovation and Technology (EIT)’s Transatlantic AI award.
As a Barcelona Innova Lab Mobility winner, Hayden AI will exhibit its technology at the Tomorrow.Mobility World Congress in Barcelona from 5 - 7 November.
About Hayden AI: At Hayden AI, we’re revolutionizing how cities solve problems and plan for the future. Our market-leading computer vision and geospatial data collection platform provides comprehensive smart city intelligence, giving cities actionable insights and situational awareness on transportation efficiency, road safety, and public services. With our advanced AI algorithms and data analytics capabilities, cities across the globe use Hayden AI’s platform to transform how they manage infrastructure assets. Learn more at www.hayden.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20240702938222/en/
Contacts
Jezabel Martínez Fábregas
jezabel.martinezfabregas@hayden.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction19.6.2026 17:53:00 EEST | Press release
Record Currency Management Ltd (RCM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce its participation in an innovative local currency bond transaction issued by the European Bank for Reconstruction and Development (EBRD), supporting the development of Mongolia's capital markets while providing institutional investors with access to attractive frontier market opportunities. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The investment forms part of Record Financial Group's broad
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom